Salivary ZG16B expression loss follows exocrine gland dysfunction related to oral chronic graft-versus-host disease
Ana Caroline Costa-da-Silva,
Marit H. Aure,
Joshua Dodge,
Daniel Martin,
Susan Dhamala,
Monica Cho,
Jeremy J. Rose,
Carol W. Bassim,
Kiran Ambatipudi,
Frances T. Hakim,
Steven Z. Pavletic,
Jacqueline W. Mays
Affiliations
Ana Caroline Costa-da-Silva
National Institute of Dental and Craniofacial Research, NIH, Building 30, MSC 4340, 30 Convent Drive, Bethesda, MD 20892, USA
Marit H. Aure
National Institute of Dental and Craniofacial Research, NIH, Building 30, MSC 4340, 30 Convent Drive, Bethesda, MD 20892, USA
Joshua Dodge
National Institute of Dental and Craniofacial Research, NIH, Building 30, MSC 4340, 30 Convent Drive, Bethesda, MD 20892, USA
Daniel Martin
National Institute of Dental and Craniofacial Research, NIH, Building 30, MSC 4340, 30 Convent Drive, Bethesda, MD 20892, USA
Susan Dhamala
National Institute of Dental and Craniofacial Research, NIH, Building 30, MSC 4340, 30 Convent Drive, Bethesda, MD 20892, USA; National Cancer Institute, NIH, Bethesda, MD 20892, USA
Monica Cho
National Cancer Institute, NIH, Bethesda, MD 20892, USA
Jeremy J. Rose
National Cancer Institute, NIH, Bethesda, MD 20892, USA
Carol W. Bassim
National Institute of Dental and Craniofacial Research, NIH, Building 30, MSC 4340, 30 Convent Drive, Bethesda, MD 20892, USA
Kiran Ambatipudi
National Institute of Dental and Craniofacial Research, NIH, Building 30, MSC 4340, 30 Convent Drive, Bethesda, MD 20892, USA
Frances T. Hakim
National Cancer Institute, NIH, Bethesda, MD 20892, USA
Steven Z. Pavletic
National Cancer Institute, NIH, Bethesda, MD 20892, USA
Jacqueline W. Mays
National Institute of Dental and Craniofacial Research, NIH, Building 30, MSC 4340, 30 Convent Drive, Bethesda, MD 20892, USA; Corresponding author
Summary: Chronic graft-versus-host disease (cGVHD) targets include the oral mucosa and salivary glands after allogeneic hematopoietic stem cell transplant (HSCT). Without incisional biopsy, no diagnostic test exists to confirm oral cGVHD. Consequently, therapy is often withheld until severe manifestations develop. This proteomic study examined saliva and human salivary gland for a biomarker profile at first onset of oral cGVHD prior to initiation of topical steroid therapy. Whole saliva collected at onset of biopsy-proven oral GVHD was assessed using liquid chromatography–coupled tandem mass spectrometry with identification of 569 proteins, of which 77 significantly changed in abundance. ZG16B, a secretory lectin protein, was reduced 2-fold in oral cGVHD saliva (p <0.05), and significantly decreased in salivary gland secretory cells affected by cGVHD. Single-cell RNA-seq analysis of healthy MSG localized ZG16B expression to two discrete acinar cell populations. Reduced ZG16B expression may indicate specific cGVHD activity and possibly general salivary gland dysfunction.
